RxDoctor Payments DataLook up a doctor →

Gary Bond, MD

Nephrology · Oklahoma City, OKNPI 1053316125

Payments from drug & device makers

$8,678in general payments, 2019–2025

Across 460 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Amgen$1K
  • Fresenius USA Marketing, Inc.$968
  • Travere Therapeutics, Inc.$810
  • Vifor Pharma, Inc.$689
  • Novartis$548
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,56799%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,678 in reported general payments places this provider in the 80th percentile of 106 nephrology providers in Oklahoma.

See all nephrology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$228,161
Medicare patients
368
Services billed
3,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$25,261
Lanthanum Carbonate20$24,529
VelphoroSucroferric Oxyhydroxide11$23,017
Sevelamer Carbonate15$7,468
EdecrinEthacrynic Acid12$4,248
Calcium Acetate17$2,497
Nifedipine ErNifedipine63$1,642
Potassium Chloride54$1,255
Metoprolol Succinate56$1,054
Torsemide13$936
Furosemide61$522
Allopurinol50$467
Carvedilol33$402
Amlodipine Besylate44$367
Valsartan22$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,244$25,26134 claims
Fresenius USA Marketing, Inc.Velphoro$968$23,01711 claims
ANI Pharmaceuticals, Inc.Valsartan$113$32622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 nephrology providers in Oklahoma.

Other nephrology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →